Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (4)

Search Parameters:
Keywords = telangiectasia macularis eruptiva perstans

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
9 pages, 4148 KiB  
Comment
Telangiectatic Mastocytosis: If It Is Not Mastocytosis, What Is It? Comment on Brockow et al. Challenges in the Diagnosis of Cutaneous Mastocytosis. Diagnostics 2024, 14, 161
by Francisco Urbina and Alicia Benavides
Diagnostics 2025, 15(11), 1370; https://doi.org/10.3390/diagnostics15111370 - 29 May 2025
Cited by 1 | Viewed by 458
Abstract
We read with great interest the recent review of Brockow et al [...] Full article
(This article belongs to the Special Issue Current Challenges in Diagnosis and Management of Mast Cell Disorders)
Show Figures

Figure 1

13 pages, 2783 KiB  
Review
Challenges in the Diagnosis of Cutaneous Mastocytosis
by Knut Brockow, Rebekka Karolin Bent, Simon Schneider, Sophie Spies, Katja Kranen, Benedikt Hindelang, Zsuzsanna Kurgyis, Sigurd Broesby-Olsen, Tilo Biedermann and Clive E. Grattan
Diagnostics 2024, 14(2), 161; https://doi.org/10.3390/diagnostics14020161 - 11 Jan 2024
Cited by 13 | Viewed by 7642
Abstract
Background: Mastocytosis is characterized by an accumulation of clonal mast cells (MCs) in tissues such as the skin. Skin lesions in mastocytosis may be clinically subtle or heterogeneous, and giving the correct diagnosis can be difficult. Methods: This study compiles personal experiences together [...] Read more.
Background: Mastocytosis is characterized by an accumulation of clonal mast cells (MCs) in tissues such as the skin. Skin lesions in mastocytosis may be clinically subtle or heterogeneous, and giving the correct diagnosis can be difficult. Methods: This study compiles personal experiences together with relevant literature, discussing possible obstacles encountered in diagnosing skin involvement in mastocytosis and cutaneous mastocytosis (CM). Results: The nomenclature of the term “CM” is ambiguous. The WHO classification defines CM as mastocytosis solely present in the skin. However, the term is also used as a morphological description, e.g., in maculopapular cutaneous mastocytosis (MPCM). This is often seen in systemic, as well as cutaneous, mastocytosis. Typical CM manifestations (MPCM), including mastocytoma or diffuse cutaneous mastocytosis (DCM), all share a positive Darier’s sign, and can thus be clinically recognized. Nevertheless, distinguishing monomorphic versus polymorphic MPCM may be challenging, even for experienced dermatologists. Less typical clinical presentations, such as MPCM with telangiectatic erythemas (formerly called telangiectasia macularis eruptiva perstans), confluent, nodular or xanthelasmoid variants may require a skin biopsy for histopathological confirmation. Because MC numbers in CM have a large overlap to those in healthy and inflamed skin, detailed histopathological criteria to diagnose mastocytosis in MPCM are needed and have been proposed. D816V KIT mutational analysis in tissue is helpful for confirming the diagnosis. Biomarkers allow the prediction of the course of CM into regression or evolution of the disease. Further diagnostic measures should screen for concomitant diseases, such as malignant melanoma, and for systemic involvement. Conclusions: Whereas in typical cases the diagnosis of CM may be uncomplicated, less typical manifestations may require specific investigations for making the diagnosis and predicting its course. Full article
(This article belongs to the Special Issue Current Challenges in Diagnosis and Management of Mast Cell Disorders)
Show Figures

Figure 1

11 pages, 2086 KiB  
Systematic Review
Dermoscopic Features of Different Forms of Cutaneous Mastocytosis: A Systematic Review
by Martyna Sławińska, Agnieszka Kaszuba, Magdalena Lange, Roman J. Nowicki, Michał Sobjanek and Enzo Errichetti
J. Clin. Med. 2022, 11(16), 4649; https://doi.org/10.3390/jcm11164649 - 9 Aug 2022
Cited by 8 | Viewed by 4395
Abstract
The term mastocytosis refers to a heterogeneous group of disorders characterised by accumulation of clonal mast cells in different organs, most commonly in the skin. Little is known about the role of dermoscopy in the diagnostics of mastocytosis. To date, no systematic review [...] Read more.
The term mastocytosis refers to a heterogeneous group of disorders characterised by accumulation of clonal mast cells in different organs, most commonly in the skin. Little is known about the role of dermoscopy in the diagnostics of mastocytosis. To date, no systematic review on the dermoscopic features of cutaneous mastocytosis has been performed. The aim of this study was to summarise the current knowledge in the field as well as to identify the knowledge gaps to show possible directions for further studies, based on a systematic search of PubMed, Scopus, and Web of Science databases and related references published before 3 January 2022. Dermoscopic features, type of dermoscope, polarisation mode, magnification, and number of cases were analysed. In total, 16 articles were included in this review (3 case series and 13 case reports), analysing 148 patients with different variants of cutaneous mastocytosis; all of the studies analysed had a low level of evidence (V). The main dermoscopic features of urticaria pigmentosa included brown structureless areas, brown lines arranged in a network, and linear vessels distributed in a reticular pattern, with this last finding also being typical of telangiectasia macularis eruptiva perstans. The presence of either circumscribed yellow structureless areas or diffuse yellowish background was a constant pattern of mastocytoma, while nodular, pseudoangiomatous xanthelasmoid, and plaque-type mastocytosis were typified by light-brown structureless areas and/or pigment network, though the first two variants also showed yellow/yellow-orange structureless areas. Finally, pigmented streaks of radial distribution surrounding hair follicles were described to be a pathognomonic dermoscopic feature of pseudoxanthomatous mastocytosis. Although this review shows that the various clinical forms of cutaneous mastocytosis may feature diagnostic dermoscopic clues, it also underlines the need for further investigation as several relevant data are missing, including evaluation of dermoscopic pattern according to anatomical locations or “lesion age”, studies on rare mastocytosis variants, evaluation of the prognostic role of dermoscopy in the context of systemic involvement, and comparative analyses with common clinical mimickers. Full article
(This article belongs to the Section Dermatology)
Show Figures

Figure 1

5 pages, 1212 KiB  
Case Report
Symptomatic Response to Imatinib Mesylate in Cutaneous Mastocytosis Associated with Chronic Myelomonocytic Leukemia
by E.J. Vannorsdall, J.A. Collins, Q.C. Chen, G. Sarai and M.R. Baer
Curr. Oncol. 2013, 20(4), 349-353; https://doi.org/10.3747/co.20.1301 - 1 Aug 2013
Cited by 7 | Viewed by 870
Abstract
Mastocytosis is an uncommon disorder defined by increased and abnormal mast cells in one or more tissues. Cutaneous mastocytosis (CM) is limited to the skin, with varying degrees of rash, pruritus, and disfigurement. Systemic mastocytosis (SM) typically involves the [...] Read more.
Mastocytosis is an uncommon disorder defined by increased and abnormal mast cells in one or more tissues. Cutaneous mastocytosis (CM) is limited to the skin, with varying degrees of rash, pruritus, and disfigurement. Systemic mastocytosis (SM) typically involves the bone marrow, sometimes in association with other bone marrow disorders, including chronic myelomonocytic leukemia (CMML). Mastocytosis has been associated with somatic mutations in the gene encoding the tyrosine kinase Kit, leading to identification of Kit as a therapeutic target. The Kit inhibitor imatinib mesylate is approved for aggressive SM. We present an unusual patient with disabling pruritus from telangiectasia macularis eruptiva perstans, a subtype of CM, and CMML, but with no evidence of systemic mast cell disease. She was treated with imatinib and experienced marked improvement in her pruritus. Concomitant CM and CMML have not previously been reported, and the present report is the first of successful imatinib therapy in an adult patient with CM. Full article
Back to TopTop